Breast Milk Has Been Fighting Germs Since the Age of Dinosaurs, Scientists Discover

Mother’s milk has long been celebrated for its immune-boosting powers, and researchers have now traced exactly how one of its protective proteins learned to kill bacteria. They did this by reconstructing ancient forms of the protein from genetic data, remaking its fragments in the lab, and then reverse-engineering evolution to watch a germ-fighting weapon take shape over deep time.

That protein is lactoferrin, found in milk, tears, saliva, and certain immune cells. Tucked inside it sits a smaller piece, a short stretch of building blocks called lactoferricin, which digestive enzymes can snip out and turn into a potent bacteria-killing fragment. Scientists at the University of Oregon wanted to know how this hidden weapon got there in the first place, and how it has kept sharpening itself over millions of years, right up to the differences that separate humans from other great apes. Their results appear in the journal PLOS Biology.

To find out, the team reconstructed what the protein likely looked like in the earliest mammals, before it even became lactoferrin. The result was a clear origin story for a molecular weapon that is still evolving in great apes today, including humans.

How Scientists Rebuilt an Ancient Protein From Deep Time

Lactoferrin has not always existed. It arose when an older, iron-carrying protein called transferrin was duplicated in the common ancestor of placental mammals, roughly 160 million years ago. Transferrin’s main job is to ferry iron through the bloodstream and hand it off to cells. Lactoferrin, born from that extra copy, picked up a second job: fighting off bacteria and other germs.

To trace that journey, the team used a method called ancestral sequence reconstruction. Drawing on hundreds of publicly available gene sequences from across the vertebrate family tree, they fed the data into specialized software that predicts what a protein’s building blocks most likely looked like at particular points in the distant past. They then had those ancient fragments synthesized in the lab and pitted them against real, living bacteria.

Researchers rebuilt four ancestral versions. One represented the protein just before the duplication, a snapshot of transferrin before lactoferrin existed. A second captured the very first lactoferrin after the split. The other two marked intermediate stages on the path to the modern human and bovine versions. For comparison, the team also tested the matching fragments from present-day human transferrin, human lactoferrin, and cow lactoferrin.

When Lactoferrin First Became a Bacteria-Killer

Researchers tested the fragments against four troublesome bacteria: Pseudomonas aeruginosa, a germ tied to hospital infections and cystic fibrosis; Escherichia coli; Staphylococcus aureus; and Streptococcus agalactiae, a cause of severe infections in newborns. A clear progression showed up.

Before the duplication, the protein barely interacted with bacteria. Right after, the first lactoferricin ancestor killed germs to a modest degree, mostly at higher doses against P. aeruginosa and E. coli. More tellingly, that earliest ancestor could do something the transferrin fragment never could: punch holes in bacterial membranes. Breaching the cell membrane is one of the main ways the immune system kills microbes, and every ancestral fragment, even the oldest, managed it.

What changed over evolutionary time was how thoroughly the job got done. Bacteria hit with the oldest ancestor often bounced back after an initial knock. Bacteria exposed to the modern cow version were dead within two hours, with no colonies left to count. Microscope images drove the point home. Cells treated with older fragments showed small, local dents in their outer membranes but otherwise looked fairly normal, while cells treated with modern bovine lactoferricin simply caved in, shrinking, rounding up, and losing their membranes into the cytoplasm. The climb was not steady, though. Human lactoferricin ended up weaker against some bacteria than certain ancestors that came long before it, so the weapon’s power rose and fell along different branches rather than marching straight upward.

So what flipped the switch? Between the first ancestral lactoferricin and the second, more potent one, the researchers found just three differences in the sequence. One mattered most: a swap at position 8, where a neutral building block called glutamine gave way to a positively charged one called arginine. To test this, the team built two altered peptides: they added arginine to the weaker ancestor and removed it from the stronger one. Adding it lifted the weaker peptide’s power against P. aeruginosa up to the stronger version’s level; removing it gutted the stronger peptide. For that germ, the single building block was both necessary and sufficient to explain the leap.

Against S. aureus, the picture got murkier. Removing arginine from the stronger ancestor wiped out its punch, so the change was clearly needed. But adding it to the weaker ancestor wasn’t enough to make that peptide a staph killer, suggesting other features of the molecule also matter. Bacteria-killing peptides do not treat every germ alike, and evolution appears to tune the weapon differently depending on the target.

Lactoferrin Is Still Evolving Inside Great Apes

Some of the sharpest changes appear to be recent, playing out within the primate family tree. Earlier work from the same lab flagged two spots in the lactoferricin fragment as evolving unusually fast across primates, suggesting natural selection was actively reshaping them.

Position 5 is especially telling. In humans and many monkeys, that slot holds a glutamine. In chimpanzees and other great apes, an arginine sits there instead. To test whether the difference matters, the team made a human lactoferricin with the great-ape version at position 5 and compared it with the standard human version. Across S. aureus and four other Staphylococcus species, the great-ape-like variant clearly outperformed the standard human one in lab tests. In other words, against these staph bacteria, humans appear to carry a slightly weaker version of this peptide than chimpanzees and other great apes do. That difference appeared specifically against staph and says nothing about whether great apes fight infection better overall. A second spot, position 12, showed subtler effects, with small but consistent differences from one species to the next.

Why Ancient Lactoferrin Could Help Fight Superbugs

Beyond charting how an immune protein evolves, the work has practical value. As antibiotic resistance keeps climbing worldwide, scientists are increasingly eyeing bacteria-killing peptides as alternatives or partners to standard drugs. Because several of these resurrected ancestors proved potent, some against germs that modern human lactoferricin struggles with, they make appealing templates for new treatments.

None of the fragments, ancient or modern, caused meaningful harm to red blood cells in lab tests, suggesting their killing power is reasonably selective for bacteria rather than cells in general. That kind of selectivity matters enormously in drug development, where collateral damage to human cells can sink an otherwise promising candidate. All of this, though, comes from experiments in lab dishes, including red-blood-cell tests that used cattle blood. Turning an ancient peptide into a safe, effective medicine for people would take years of further testing.

Breast milk’s reputation as a health powerhouse, it turns out, runs deep into evolutionary history, and the protein behind it has been fine-tuning its killing strategy for some 160 million years. The fact that it is still changing in living primates suggests the ancient arms race between mammals and bacteria is nowhere near over.

---